ALGN ALIGN TECHNOLOGY INC
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1097149 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.4%
TTM net income YoY30.0%
TTM EPS YoY32.9%
Revenue 3-yr CAGR3.0%
Net income 3-yr CAGR10.7%
Margins
Gross margin69.1%
Operating margin14.9%
Net margin11.8%
FCF margin14.5%
EBITDA margin20.6%
Returns
ROE11.9%
ROA7.7%
ROIC (approx.)15.5%
Asset turnover0.65x
Leverage & solvency
Liabilities / assets34.0%
Debt / equity0.00x
Current ratio1.42x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.52x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue3.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.01B | $1.06B | $1.04B | $1.05B | $995.69M | $1.01B | $979.26M | $995.22M |
| Cost of revenue | $317.29M | $298.76M | $303.50M | $363.97M | $356.49M | $304.33M | $299.15M | $298.28M |
| Gross profit | $697.47M | $757.43M | $736.59M | $683.59M | $639.20M | $708.12M | $680.11M | $696.94M |
| R&D expense | $93.87M | $102.03M | $98.66M | $83.04M | $93.28M | $96.40M | $97.20M | $94.88M |
| SG&A expense | $410.55M | $462.67M | $465.34M | $441.68M | $417.80M | $448.69M | $447.63M | $424.97M |
| Operating income | $169.16M | $154.01M | $141.96M | $155.32M | $96.30M | $163.03M | $131.10M | $144.15M |
| Pretax income | $170.07M | $148.69M | $148.89M | $176.59M | $94.73M | $173.52M | $140.44M | $140.78M |
| Income tax | $35.03M | $40.40M | $36.12M | $40.84M | $37.98M | $48.91M | $47.21M | $36.97M |
| Net income | $135.04M | $108.29M | $112.77M | $135.76M | $56.75M | $124.61M | $93.23M | $103.81M |
| EBITDA | $208.61M | $194.14M | $198.50M | $257.32M | $152.01M | $203.61M | $170.25M | $182.28M |
| EPS (basic) | 1.90 | 1.51 | 1.58 | — | 0.78 | 1.72 | 1.27 | — |
| EPS (diluted) | 1.90 | 1.51 | 1.57 | — | 0.78 | 1.72 | 1.27 | — |
| Weighted avg. shares (diluted) | 71.02M | 71.52M | 71.61M | — | 72.42M | 72.59M | 73.61M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.14B | $1.10B | $1.06B | $1.09B | $1.01B | $902.34M | $874.07M | $1.04B |
| Short-term investments | — | — | — | — | — | — | — | $0 |
| Receivables | $1.16B | $1.15B | $1.13B | $1.10B | $1.10B | $1.12B | $1.06B | $995.68M |
| Inventory | $224.65M | $212.24M | $214.94M | $226.34M | $228.16M | $243.75M | $246.57M | $254.29M |
| Current assets | $2.73B | $2.66B | $2.66B | $2.62B | $2.53B | $2.45B | $2.40B | $2.49B |
| PP&E, net | $1.13B | $1.11B | $1.11B | $1.13B | $1.18B | $1.26B | $1.26B | $1.27B |
| Goodwill | $495.28M | $497.30M | $503.04M | $491.83M | $491.52M | $491.07M | $457.61M | $442.63M |
| Intangibles | $90.62M | $94.93M | $100.82M | $93.93M | $98.72M | $103.48M | $102.75M | $103.49M |
| Total assets | $6.52B | $6.42B | $6.31B | $6.23B | $6.23B | $6.22B | $6.10B | $6.21B |
| Current liabilities | $1.91B | $1.91B | $1.91B | $1.92B | $1.97B | $2.00B | $1.99B | $2.04B |
| Total liabilities | $2.22B | $2.19B | $2.16B | $2.18B | $2.28B | $2.31B | $2.31B | $2.36B |
| Shareholders' equity | $4.31B | $4.23B | $4.15B | $4.05B | $3.96B | $3.91B | $3.79B | $3.85B |
| Shares outstanding | 70.69M | 71.25M | 71.62M | 71.36M | 72.04M | 72.49M | 73.06M | 73.85M |
| Cash flow statement | ||||||||
| Operating cash flow | $182.92M | $192.76M | $151.04M | $223.18M | $188.72M | $128.65M | $52.68M | $286.08M |
| Capital expenditure | $45.03M | $35.66M | $30.79M | $35.92M | $19.76M | $21.48M | $25.29M | $22.96M |
| Free cash flow | $137.89M | $157.09M | $120.26M | $187.26M | $168.96M | $107.17M | $27.39M | $263.12M |
| Investing cash flow | -$47.06M | -$82.16M | -$131.58M | -$35.92M | -$19.76M | -$31.48M | -$25.29M | -$53.92M |
| Financing cash flow | -$94.92M | -$67.45M | -$48.13M | -$97.41M | -$64.12M | -$96.30M | -$206.76M | -$203.02M |
| Depreciation & amortization | $39.45M | $40.13M | $56.55M | $102.00M | $55.72M | $40.58M | $39.15M | $38.13M |
| Stock-based compensation | $39.03M | $45.56M | $40.92M | $44.29M | $48.38M | $48.21M | $45.00M | $38.85M |
| Share buybacks | $103.06M | $66.93M | $31.20M | $97.25M | $71.56M | $96.05M | $201.09M | $202.87M |
Free plan shows the latest 8 periods; Pro shows all 71 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.